Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)
Advanced Solid Tumors · Triple Negative Breast Cancer · Ovarian Cancer · Gastric Cancer · Colorectal Cancer · Glioblastoma · Biliary Tract Cancers · Pancreatic Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 2
- Patients
- 611 (final count)
- Started
- Feb 12, 2019
- Main results expected
- Oct 28, 2024
- Fully finished
- Oct 28, 2024
- Results posted
- Nov 17, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Investigator Assessment
Measured over: Up to approximately 66 months
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) or Response Assessment in Neuro-Oncology (RANO) Criteria (for Glioblastoma Multiforma [GBM] Only), by Blinded Independent Central Review (BICR)
Measured over: Up to approximately 66 months
Number of Participants With One or More Adverse Events (AEs)
Measured over: Up to approximately 66 months
Number of Participants Who Discontinued From Study Treatment Due to an AE
Measured over: Up to approximately 62 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT03797326 · record last updated 2026-05-04 · checked 2026-11-09 15:47 UTC